Radar›Companies›Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 1
United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 1

A five-company biological products, excluding disgnostic substances cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness
Readiness leaderGilead · 65
Strongest available pathExelixis · +169.1%
Widest latest marginExelixis · 33.7%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1GILD · Nasdaq

Gilead

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2015Palo Alto, California$185.89B market cap
View full Companies Radar profile
65Solid
Snapshot price$149.9as of page date
Monthly-close return+114.6%five-year window
FY2025 revenue$29.44BGILEAD SCIENCES, INC.
Net margin28.9%FY2025
P/E snapshot15.2xone ratio, not a verdict
Prism attention19.1%share across these five
Filing track recordRevenue, USD billions
+7.8%
$0$9.8B$19.6B$29.4BFY2021: $27.305BFY2022: $27.281BFY2023: $27.116BFY2024: $28.754BFY2025: $29.443B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.9%
52-week position85% through range
$108.5$157.3
News mentions45.0K
Community mentions8.1Kpartial coverage
U.S.-scope patents13744
Prism Insights

What sits behind the readiness signal

Observed risk 8/100higher means more observed risk
Earnings signal77/100
Management stability90/100
Market position52/100
Capital-event signal90/100
Innovation pulse22/100
Management signal

No leadership-churn flag in the model; 6 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 96 M&A involvements, 13 asset-acquisition events and 40 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

Recent available records contain 4 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2MRNA · Nasdaq

Moderna

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2010Cambridge, Massachusetts$61.59B market cap
View full Companies Radar profile
62Moderate
Snapshot price$154.3as of page date
Monthly-close return-59.9%five-year window
FY2025 revenue$1.94BModerna, Inc.
Net margin-145.2%FY2025
P/E snapshot-33.3xone ratio, not a verdict
Prism attention78.3%share across these five
Filing track recordRevenue, USD billions
+3128.8%
$0$2.3B$4.6B$6.8BFY2019: $0.060BFY2023: $6.848BFY2024: $3.236BFY2025: $1.944B2019202320242025
FY2019–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 218.4%
52-week position85% through range
$22.28$176.7
News mentions185.1K
Community mentions40.7Kpartial coverage
U.S.-scope patents2823
Prism Insights

What sits behind the readiness signal

Observed risk 14/100higher means more observed risk
Earnings signal81/100
Management stability90/100
Market position46/100
Capital-event signal90/100
Innovation pulse20/100
Management signal

No leadership-churn flag in the model; 6 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 38 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 4 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3RGEN · Nasdaq

Repligen

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1981Waltham$9.60B market cap
View full Companies Radar profile
60Moderate
Snapshot price$170.0as of page date
Monthly-close return-41.2%five-year window
FY2025 revenue$0.74BREPLIGEN CORP
Net margin6.6%FY2025
P/E snapshot236.1xone ratio, not a verdict
Prism attention0.6%share across these five
Filing track recordRevenue, USD billions
+10.1%
$0$0.3B$0.5B$0.8BFY2021: $0.671BFY2022: $0.802BFY2023: $0.639BFY2024: $0.634BFY2025: $0.738B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.4%
52-week position79% through range
$101.0$188.7
News mentions1.5K
Community mentions0partial coverage
U.S.-scope patents578
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal69/100
Management stability90/100
Market position24/100
Capital-event signal65/100
Innovation pulse39/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 33 M&A involvements, 4 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 3 lifetime product-launch events, 3 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4HALO · Nasdaq

Halozyme

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1999San Diego, California$12.23B market cap
View full Companies Radar profile
59Moderate
Snapshot price$107.7as of page date
Monthly-close return+164.8%five-year window
FY2025 revenue$1.40BHALOZYME THERAPEUTICS, INC.
Net margin22.7%FY2025
P/E snapshot31.6xone ratio, not a verdict
Prism attention0.9%share across these five
Filing track recordRevenue, USD billions
+215.0%
$0$0.5B$0.9B$1.4BFY2021: $0.443BFY2022: $0.660BFY2023: $0.829BFY2024: $1.015BFY2025: $1.397B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 33.2%
52-week position96% through range
$61.23$109.7
News mentions2.1K
Community mentions0partial coverage
U.S.-scope patents731
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal73/100
Management stability90/100
Market position38/100
Capital-event signal71/100
Innovation pulse10/100
Management signal

No leadership-churn flag in the model; 4 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 15 M&A involvements, 1 asset-acquisition events and 8 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5EXEL · Nasdaq

Exelixis

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1994San Francisco, California$14.10B market cap
View full Companies Radar profile
58Moderate
Snapshot price$56.89as of page date
Monthly-close return+169.1%five-year window
FY2025 revenue$2.32BEXELIXIS, INC.
Net margin33.7%FY2025
P/E snapshot17.9xone ratio, not a verdict
Prism attention1.1%share across these five
Filing track recordRevenue, USD billions
+61.7%
$0$0.8B$1.5B$2.3BFY2021: $1.435BFY2022: $1.611BFY2023: $1.830BFY2024: $2.169BFY2025: $2.320B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.8%
52-week position97% through range
$33.76$57.57
News mentions2.5K
Community mentions0partial coverage
U.S.-scope patents2645
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal82/100
Management stability90/100
Market position15/100
Capital-event signal80/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 7 M&A involvements, 2 asset-acquisition events and 11 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Exelixis
+169.1%
Halozyme
+164.8%
Gilead
+114.6%
Repligen
-41.2%
Moderna
-59.9%

Latest revenue

USD billions, official filing scope shown on each company card.

Gilead
$29.44B
Exelixis
$2.32B
Moderna
$1.94B
Halozyme
$1.40B
Repligen
$0.74B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Exelixis
33.7%
Gilead
28.9%
Halozyme
22.7%
Repligen
6.6%
Moderna
-145.2%

Prism news attention

Normalized share across these five names; attention is not quality.

Moderna
78.3%
Gilead
19.1%
Exelixis
1.1%
Halozyme
0.9%
Repligen
0.6%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Moderna leads the conversation

It holds 78.3% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $1.94B.

Price path

Exelixis leads the available price paths

Its monthly-close return is +169.1% for the five-year window. At the other end, Moderna is -59.9% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Exelixis has the widest latest margin

Its FY2025 net margin is 33.7%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Moderna shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -33.3x while its five-year window price return is -59.9%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · GILD

Gilead

45,041available Prism news records

Prism top themes

Legal, arbitration & regulatory
268
Capital allocation & transactions
259
Price action & investor response
239
Earnings & financial performance
188
Macro demand & rates
148

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+10.7%5,601 latest 12m vs 5,059 prior 12m
2024-02: 338 mentions2024-03: 350 mentions2024-04: 235 mentions2024-05: 328 mentions2024-06: 310 mentions2024-07: 289 mentions2024-08: 305 mentions2024-09: 234 mentions2024-10: 273 mentions2024-11: 293 mentions2024-12: 291 mentions2025-01: 306 mentions2025-02: 1,117 mentions2025-03: 356 mentions2025-04: 690 mentions2025-05: 538 mentions2025-06: 278 mentions2025-07: 378 mentions2025-08: 407 mentions2025-09: 291 mentions2025-10: 267 mentions2025-11: 317 mentions2025-12: 759 mentions2026-01: 391 mentions2026-02: 503 mentions2026-03: 501 mentions2026-04: 1,230 mentions2026-05: 514 mentions2026-06: 419 mentions2026-07: 2 mentions2024-022026-07

Machine-classified coverage tone

84.5% positive+8.1 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

conceptual rock albums 381genre-defying rock 381symphonic rock pieces 380narrative-driven rock 380technical rock journeys 380avant-garde rock 380unconventional rock instruments 380psychedelic textures 380

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-07-14 · trend and themes shown through 2026-07
Areas of research · MRNA

Moderna

185,148available Prism news records

Prism top themes

Macro demand & rates
963
Price action & investor response
459
Legal, arbitration & regulatory
277
Leadership & governance
102

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-54.2%5,259 latest 12m vs 11,494 prior 12m
2024-03: 354 mentions2024-04: 438 mentions2024-05: 622 mentions2024-06: 636 mentions2024-07: 464 mentions2024-08: 725 mentions2024-09: 715 mentions2024-10: 498 mentions2024-11: 533 mentions2024-12: 392 mentions2025-01: 673 mentions2025-02: 643 mentions2025-03: 455 mentions2025-04: 434 mentions2025-05: 1,144 mentions2025-06: 440 mentions2025-07: 1,054 mentions2025-08: 4,513 mentions2025-09: 745 mentions2025-10: 441 mentions2025-11: 354 mentions2025-12: 446 mentions2026-01: 452 mentions2026-02: 1,270 mentions2026-03: 415 mentions2026-04: 453 mentions2026-05: 494 mentions2026-06: 186 mentions2026-07: 1 mentions2026-08: 2 mentions2024-032026-08

Machine-classified coverage tone

61.0% positive+8.0 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

vaccine candidates 5,598vaccine trials 5,267vaccine immunogenicity 4,712vaccination campaigns 4,360mass vaccination sites 2,861vaccination coverage 2,114vaccine effectiveness study 2,030vaccine durability 1,897

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-06–2026-08-05 · trend and themes shown through 2026-08
Areas of research · RGEN

Repligen

1,487available Prism news records

Prism top themes

Earnings & financial performance
113
Price action & investor response
102
Leadership & governance
24
Capital allocation & transactions
23
Legal, arbitration & regulatory
12

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-27.4%262 latest 12m vs 361 prior 12m
2024-01: 7 mentions2024-02: 12 mentions2024-03: 13 mentions2024-04: 8 mentions2024-05: 31 mentions2024-06: 18 mentions2024-07: 25 mentions2024-08: 9 mentions2024-09: 8 mentions2024-10: 9 mentions2024-11: 14 mentions2024-12: 9 mentions2025-01: 10 mentions2025-02: 215 mentions2025-03: 21 mentions2025-04: 21 mentions2025-05: 12 mentions2025-06: 8 mentions2025-07: 25 mentions2025-08: 14 mentions2025-09: 28 mentions2025-10: 24 mentions2025-11: 17 mentions2025-12: 18 mentions2026-01: 26 mentions2026-02: 27 mentions2026-03: 15 mentions2026-04: 34 mentions2026-05: 28 mentions2026-06: 6 mentions2024-012026-06

Machine-classified coverage tone

92.5% positive+2.2 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 25earnings report 23quarterly results 21annual earnings 19stock price 15stock surge 11annual results 11biosignal processing 9

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-26–2026-06-19 · trend and themes shown through 2026-06
Areas of research · HALO

Halozyme

2,133available Prism news records

Prism top themes

Earnings & financial performance
83
Price action & investor response
79
Capital allocation & transactions
61
Leadership & governance
38
Legal, arbitration & regulatory
29

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-4.5%359 latest 12m vs 376 prior 12m
2024-01: 29 mentions2024-02: 14 mentions2024-03: 7 mentions2024-04: 8 mentions2024-05: 33 mentions2024-06: 30 mentions2024-07: 16 mentions2024-08: 13 mentions2024-09: 21 mentions2024-10: 14 mentions2024-11: 51 mentions2024-12: 11 mentions2025-01: 27 mentions2025-02: 115 mentions2025-03: 36 mentions2025-04: 29 mentions2025-05: 27 mentions2025-06: 16 mentions2025-07: 5 mentions2025-08: 13 mentions2025-09: 17 mentions2025-10: 29 mentions2025-11: 45 mentions2025-12: 51 mentions2026-01: 45 mentions2026-02: 28 mentions2026-03: 35 mentions2026-04: 43 mentions2026-05: 40 mentions2026-06: 8 mentions2024-012026-06

Machine-classified coverage tone

94.9% positive+5.7 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

company valuation 26angel investors 19earnings report 16quarterly results 16generic drug approval 14adc therapeutics 14stock performance 14startup valuation 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-15–2026-06-15 · trend and themes shown through 2026-06
Areas of research · EXEL

Exelixis

2,485available Prism news records

Prism top themes

Price action & investor response
108
Earnings & financial performance
76
Capital allocation & transactions
29
Legal, arbitration & regulatory
20
Leadership & governance
12

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-51.1%247 latest 12m vs 505 prior 12m
2024-03: 31 mentions2024-04: 7 mentions2024-05: 23 mentions2024-06: 11 mentions2024-07: 12 mentions2024-08: 14 mentions2024-09: 17 mentions2024-10: 34 mentions2024-11: 10 mentions2024-12: 12 mentions2025-01: 34 mentions2025-02: 226 mentions2025-03: 39 mentions2025-04: 24 mentions2025-05: 20 mentions2025-06: 47 mentions2025-07: 18 mentions2025-08: 24 mentions2025-09: 24 mentions2025-10: 26 mentions2025-11: 4 mentions2025-12: 12 mentions2026-01: 44 mentions2026-02: 50 mentions2026-03: 14 mentions2026-04: 20 mentions2026-05: 42 mentions2026-06: 10 mentions2026-07: 0 mentions2026-08: 1 mentions2024-032026-08

Machine-classified coverage tone

95.3% positive+2.4 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 58angiogenesis inhibitors 28stock price 28cancer biomarkers 15share price 13earnings report 13stock surge 13annual earnings 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-08-04 · trend and themes shown through 2026-08
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

GILD

Gilead

8,101 mentions
Stock and valuation
3,626
Products, pricing and logistics
2,029
Workplace and hiring
183
Other company context
20

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 8,101 records remained after filtering.

MRNA

Moderna

40,700 mentions
Products, pricing and logistics
13,383
Stock and valuation
10,662
Workplace and hiring
321
Other company context
85

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 40,700 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

GILD

Gilead

through 2026-04-28
Earnings releases 58M&A 36Leadership changes 15Listing / IPO 9Company announcements 8
  1. M&A

    Gilead completed its acquisition of Arcellx through the merger of Purchaser with and into Arcellx, and without a meeting of the stockholders of Arcellx in accordance with Section 251(h) of the DGCL, with Arcellx surviving such Merger as a wholly owned subsidiary of Gilead.

  2. Asset acquisitions

    Gilead Sciences, Inc. today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx.

  3. Lawsuits

    Halper Sadeh LLC is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Arcellx, Inc. (NASDAQ: ACLX )'s sale to Gilead Sciences, Inc. for $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

MRNA

Moderna

through 2026-05-01
Earnings releases 65Company announcements 37Leadership changes 12Business contracts 10Regulatory 8
  1. Earnings releases

    For the first quarter, total revenue was $400 million, coming in above our guidance and represents a $300 million increase versus the prior year.

  2. Regulatory

    In February, the FDA initially refused to review the mRNA-1010 flu vaccine.

  3. Business contracts

    Tuesday, April 28, 2026 – Salesforce today announced that Moderna has selected Salesforce’s Agentforce Life Sciences for Customer Engagement to unify the biotechnology company’s global commercial operations.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RGEN

Repligen

through 2026-02-26
Earnings releases 36Leadership changes 18M&A 16Company announcements 4Listing / IPO 2
  1. Earnings releases

    Repligen (NASDAQ:RGEN) management said the company capped 2025 with a “great finish,” posting fourth-quarter revenue of $198 million and full-year revenue of $738 million.

  2. Leadership changes

    On September 2, 2025, Repligen Corporation announced the appointment of Violetta Hughes as the new Chief Accounting Officer, effective September 1, 2025.

  3. Asset acquisitions

    On Tuesday, Repligen Corporation (NASDAQ:RGEN) purchased 908 Devices Inc.’s (NASDAQ:MASS) desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

HALO

Halozyme

through 2026-02-17
Earnings releases 47M&A 10Leadership changes 9Business contracts 3Regulatory 3
  1. Earnings releases

    Total revenue in the fourth quarter was $451.8 million, compared to $298.0 million in the fourth quarter of 2024. Net loss in the fourth quarter was $141.6 million, compared to net income of $137.0 million in the fourth quarter of 2024.

  2. M&A

    To take over Surf, Halozyme is paying $300 million upfront, subject to customary purchase price adjustments, and up to $100 million in development and regulatory milestones.

  3. Business contracts

    Leerink notes Halozyme (HALO) issued a press release announcing that it entered into an exclusive license agreement with Takeda (TAK) in December 2025 to develop an ENHANZE version of Entyvio.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EXEL

Exelixis

through 2026-01-11
Earnings releases 19Listing / IPO 11Leadership changes 9M&A 7Board updates 4
  1. Earnings releases

    Total revenues ~ $2.32 0 billion

  2. Listing / IPO

    By Mary Welch The shaky market did just fine by Exelixis Inc., as the company raised $118 million in its initial public offering by selling 9.1 million shares at $13 each.

  3. M&A

    Exelixis Inc. entered a definitive agreement to acquire X-Ceptor Therapeutics Inc.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence
2020 extracted base$194.20B–$477.15B
2033 extracted forecast$685.30B–$1.37T
Implied source CAGR8.5%
high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records
Latest 12m volume+9.8%10786 vs 9825 records
Positive classified tone41.7%+4.6 pp vs prior four quarters
2024-01: 892 mentions2024-02: 804 mentions2024-03: 821 mentions2024-04: 790 mentions2024-05: 1,080 mentions2024-06: 758 mentions2024-07: 563 mentions2024-08: 879 mentions2024-09: 628 mentions2024-10: 779 mentions2024-11: 620 mentions2024-12: 655 mentions2025-01: 712 mentions2025-02: 1,067 mentions2025-03: 1,362 mentions2025-04: 999 mentions2025-05: 803 mentions2025-06: 593 mentions2025-07: 966 mentions2025-08: 3,062 mentions2025-09: 751 mentions2025-10: 687 mentions2025-11: 634 mentions2025-12: 660 mentions2026-01: 312 mentions2026-02: 1,077 mentions2026-03: 634 mentions2026-04: 1,323 mentions2026-05: 87 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies
4,078
substance abuse education
3,736
opioid addiction and treatment
3,643
overdose prevention techniques
3,482
controlled substance regulations
3,381
substance abuse overdose fatalities
3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576psychedelic mental health studies 1,328cannabis policy reform discussions 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 1–8. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Exelixis has the widest attention-readiness rank gap

It ranks #3 by measured news attention (1.1%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Exelixis in Companies Radar

Moderna shows a price-operating divergence to inspect

Its displayed filing-revenue change is +3128.8% while its available monthly-close return is -59.9%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Moderna in Companies Radar
Explanations

Attention measures coverage volume, not quality

Moderna's 78.3% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Moderna in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Gilead's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 65/100 score.

Open Gilead in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon